Journal of Biological Chemistry · 1996 · 57 citations · 34 references
Life SciencesGeneticsImmunologyCellular MetabolismDevelopmental ImmunologyImmunogeneticsEnzyme DeficienciesFetal PhysiologyInborn Errors Of MetabolismMaternal-fetal Immune InteractionsMaternal-fetal PhysiologyPlacental DevelopmentAdenosine Deaminase DeficiencyAutosomal Recessive ImmunodeficiencyGene DisruptionImmunodeficiency Disease ModelsImmunologic DysregulationMaternal-fetal ImmunologyPurine CatabolismTargeted Gene Disruption
Adenosine deaminase (ADA; EC) deficiency in humans is an autosomal recessive genetic disorder that results in severe combined immunodeficiency disease. ADA-deficient mice generated by targeted gene disruption die perinatally, preventing postnatal analysis of ADA deficiency. We have recently rescued ADA-deficient fetuses from perinatal lethality by expression of an ADA minigene in the placentas of ADA-deficient fetuses, thus generating postnatal mice admissible to analysis of ADA deficiency. The minigene used also directed ADA expression to the forestomach postnatally, producing adult animals that lacked ADA enzymatic activity in all tissues outside the gastrointestinal tract. Mice with limited ADA expression exhibited profound disturbances in purine metabolism, including thymus-specific accumulations of deoxyadenosine and dATP, and inhibition of S-adenosylhomocysteine hydrolase in the thymus, spleen, and, to a lesser extent, the liver. Lymphopenia and mild immunodeficiency were associated with these tissue-specific metabolic disturbances. These mice represent the first genetic animal model for ADA deficiency and provide insight into the tissue-specific requirements of ADA. Adenosine deaminase (ADA; EC) deficiency in humans is an autosomal recessive genetic disorder that results in severe combined immunodeficiency disease. ADA-deficient mice generated by targeted gene disruption die perinatally, preventing postnatal analysis of ADA deficiency. We have recently rescued ADA-deficient fetuses from perinatal lethality by expression of an ADA minigene in the placentas of ADA-deficient fetuses, thus generating postnatal mice admissible to analysis of ADA deficiency. The minigene used also directed ADA expression to the forestomach postnatally, producing adult animals that lacked ADA enzymatic activity in all tissues outside the gastrointestinal tract. Mice with limited ADA expression exhibited profound disturbances in purine metabolism, including thymus-specific accumulations of deoxyadenosine and dATP, and inhibition of S-adenosylhomocysteine hydrolase in the thymus, spleen, and, to a lesser extent, the liver. Lymphopenia and mild immunodeficiency were associated with these tissue-specific metabolic disturbances. These mice represent the first genetic animal model for ADA deficiency and provide insight into the tissue-specific requirements of ADA.
34
ADENOSINE-DEAMINASE DEFICIENCY IN TWO PATIENTS WITH SEVERELY IMPAIRED CELLULAR IMMUNITY
E.R. Giblett, JeanneE. Anderson, Flossie Cohen et al. · The Lancet · 1972 · 1.7K citations
Dennis A. Carson, Jonathan Kaye, J. Edwin Seegmiller · Proceedings of the National Academy of Sciences · 1977 · 414 citations · Full text
Mary Sue Colemán, James C. Donofrio, John J. Hutton et al. · Journal of Biological Chemistry · 1978 · 279 citations · Full text